Business
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.\n\n\nDate/Time: Sunday, September 17, 2023, from 20:00 – 21:00 CEST / 2:00 – 3:00 PM EDT (Sneak Peak)\nDate/Time: Monday, September 18, 2023, from 19:30 – 21:00 CEST / 1:30 – 3:00 PM EDT\nAbstract Number: 663\nPoster Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity”\nLocation: Poster Hall Exhibit\nPresenter: Kimberly Mills, PharmD\n\n\nFurther information about the ESWI Influenza Conference can be found here.\n\n\nAbout Enanta Pharmaceuticals, Inc.\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).\n\n\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET®.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230917800366/en/\n\nMedia and Investors\nJennifer Viera\n617-744-3848\[email protected]\n\n\nSource: Enanta Pharmaceuticals, Inc.","length":3845,"tagName":"div"}]